AstraZeneca (AZ; NASDAQ: AZN) has secured an exclusive licensing agreement with biotechnology firm Omniose for up to three years, gaining access to Omniose’s enzyme-based bioconjugation platform. This platform will be utilized for the development of vaccines targeting bacterial pathogens, including those that are multidrug-resistant. Omniose’s proprietary enzyme technology enables the attachment of a broader spectrum of polysaccharide antigens to engineered carrier proteins, preserving the natural structure of the polysaccharides. This approach is expected to yield a higher quality of immunization compared to traditional chemical conjugation methods, potentially revolutionizing the development of vaccines in this space.
The financial specifics of the agreement have not been disclosed, highlighting the strategic nature of this collaboration within the vaccine development landscape.- Flcube.com
